Dr. Ginsberg urges clinicians to consider onabotulinumtoxinA for OAB and urinary incontinence

"This work and previous work supports the idea that EBV not only causes MS, but also continues to affect disease progression," write the authors.

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

These findings may help guide decision-making in the initial testing phase of the [sacral neuromodulation] device prior to permanent implant or explant, according to Bradley Gill, MD, of the Cleveland Clinic.

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

In total, the prospective SOPHIA study enrolled 6 men with stress urinary incontinence who have reduced outlet resistance due to intrinsic sphincter deficiency.

The phase 3 URO-901-3005 study met its 2 co-primary end points with vibegron demonstrating a reduction in micturition episodes and urgency episodes from baseline to 12 weeks.